Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 Already well respected for accuracy, ... expanding its Length Gauge offerings with new variants of ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length gauge series ... Two new 1Vpp, 12mm stroke length variants of the ... is a variant with a weak spring, 0.4N of ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
(Date:2/26/2015)...  Epic Sciences announced today that President and CEO ... 35th Annual Cowen and Company Health Care Conference on Wednesday, ... 3rd Floor. The conference will be held at the ... Epic is developing diagnostic tests of high clinical utility ... that occur during the course of cancer treatments. From ...
(Date:2/26/2015)... Brooklyn, New York (PRWEB) February 26, 2015 ... nonprofit organization dedicated to building a nationwide Clostridium difficile ... a new C. diff burden study by the Centers ... that C. diff caused almost half a million infections ... 100,000 in U.S. nursing homes. , The study ...
Breaking Biology Technology:Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... , April 27 The Johns Hopkins University School ... establishing a collaborative program to advance the development and use of stem cells ... program will train researchers to use stem cells and foster joint research projects. ... The collaborative program will encompass ...
... ... Medical Systems Biology Initiative to Study Infectious Diseases of Fungal Pathogens. , ... (PRWEB) April 27, 2010 -- ... research, today announced that Genedata Phylosopher has been adopted by the “Dr. Jekyll & ...
... ... offer GLP/GMP certified hosting services. , ... Annapolis, MD (Vocus) April 27, 2010 -- Sidus BioData, Life Science ... RURO. RURO’s leading edge laboratory applications can now be hosted from Sidus BioData’s ...
Cached Biology Technology:The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 3The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 4The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 5German MedSys Project Adopts Genedata Phylosopher for Research Informatics 2German MedSys Project Adopts Genedata Phylosopher for Research Informatics 3Sidus BioData Partners with Life Science Software Provider RuRo 2
(Date:1/22/2015)... , Europe,s most prestigious ... Office to present a video retrospective of the most exciting and ... Christofer Toumazou and Sophie Wilson   A ... Award   Starting on 22 January 2015 on   http://www.epo.org/european-inventor ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... Conference Schedule , The following schedule of press ... Ocean Sciences Meeting. Press conferences may be added or ... may change. All updates to this schedule will be ... County Convention Center). Press conferences take place in the ...
... and biochemistry, has received the National Science Foundation,s ... highly competitive funding award, designed to support the ... in their careers, is bestowed on those scientists ... academic leaders of the 21st century. Fewer than ...
... DC and Cambridge, MA February 29, 2008 ... Commons, and the Association of Research Libraries (ARL) have ... medical school administrators ensure their institutions comply with public ... of National Institutes of Health (NIH) funding. Effective ...
Cached Biology News:2008 Ocean Sciences Meeting -- media advisory 2 22008 Ocean Sciences Meeting -- media advisory 2 32008 Ocean Sciences Meeting -- media advisory 2 42008 Ocean Sciences Meeting -- media advisory 2 52008 Ocean Sciences Meeting -- media advisory 2 62008 Ocean Sciences Meeting -- media advisory 2 72008 Ocean Sciences Meeting -- media advisory 2 82008 Ocean Sciences Meeting -- media advisory 2 9UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 2UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 3New whitepaper offers options for university implementation of NIH policy 2
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... The c-Jun proto-oncogene was first identified as the ... oncogene. Jun B and Jun D have been ... their C-terminal regions, which are involved in dimerization ... are involved in transcriptional activation, diverge. ...
...
Biology Products: